The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Covid‐19 vaccines and variants of concern: A review
Open accessAbstract
Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of confirmed infections has risen to more than 242 million worldwide, with nearly 5 million deaths. Currently, nine Covid‐19 vaccine candidates based on the original Wuhan‐Hu‐1 strain are at the forefront of vaccine research. All nine had an efficacy over 50% against symptomatic Covid‐19 disease: NVX‐CoV2373 (∼96%), BNT162b2 (∼95%), mRNA‐1273 (∼94%), Sputnik V (∼92%), AZD1222 (∼81%), BBIBP‐CorV (∼79%), Covaxin (∼78%), Ad26.CoV.S (∼66%) and CoronaVac (∼51%). However, vaccine efficacy (VE) can be jeopardised by the rapid emergence and spread of SARS‐CoV‐2 variants of concern (VOCs) that could escape from neutralising antibodies and/or cell‐mediated immunity. Rare adverse events have also been reported soon after administration of viral vector and mRNA vaccines. Although many Covid‐19 vaccines have been developed, additional effective vaccines are still needed to meet the global demand. Promising Covid‐19 vaccines such as WIBP‐CorV, AD5‐nCOV, ZyCoV‐D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. This review describes the most relevant mutations in the SARS‐CoV‐2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid‐19 vaccination and introduces some promising Covid‐19 vaccine candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 3×
“The preliminary data from phase 2/3 clinical trials demonstrated that BNT162b2 had 95% efficacy in preventing symptomatic SARS‐CoV‐2 infections.(62) The quick spread of UK and South Africa variants (both encoding”
BackgroundMethodInfluentialEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,403
WHO Declares COVID-19 a Pandemic.
Cucinotta, D., & Vanelli, M. (2020) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v91i1.9397 · Cited by 7,457
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z.-L. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,515
The proximal origin of SARS-CoV-2
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0820-9 · Cited by 5,081
Mental health and the COVID-19 pandemic
Pfefferbaum, B., & North, C. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2008017 · Cited by 4,378
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
Structure, Function, and Evolution of Coronavirus Spike Proteins
Li, F. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-042301 · Cited by 2,740
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397
Huang, Y., Yang, C., Xu, X.-F., Xu, W., & Liu, S.-W. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0485-4 · Cited by 2,224
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034201 · Cited by 1,208
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178 · cited 1×
“As a consequence, it could alter the effectiveness of current vaccines.(38)”
BackgroundGreaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026920 · Cited by 1,156
Xia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G. F., Tan, W., Wu, G., Xu, M., Lou, Z., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30831-8 · Cited by 1,144
Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107659 · Cited by 1,085
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066
Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104974 · Cited by 899
Structure analysis of the receptor binding of 2019-nCoV
Chen, Y., Guo, Y., Pan, Y., & Zhao, Z. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.071 · Cited by 806
Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789
Al Kaabi, N., Zhang, Y., Xia, S., Yang, Y., Al Qahtani, M. M., Abdulrazzaq, N., Al Nusair, M., Hassany, M., Jawad, J. S., Abdalla, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.8565 · Cited by 776
Structural insights into coronavirus entry
(2019) · Advances in Virus Research · doi:10.1016/bs.aivir.2019.08.002 · Cited by 769
Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., et al. (2020) · JAMA · doi:10.1001/jama.2020.15543 · Cited by 759
Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.008 · Cited by 748
The 2019‐new coronavirus epidemic: Evidence for virus evolution
Benvenuto, D., Giovanetti, M., Ciccozzi, A., Spoto, S., Angeletti, S., & Ciccozzi, M. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25688 · Cited by 713
Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., & Wu, J. T. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.26.1.2002106 · Cited by 694
Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103055 · Cited by 625
Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · doi:10.1101/2021.02.25.21252477 · Cited by 625
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19
Sharma, O., Sultan, A. A., Ding, H., & Triggle, C. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585354 · Cited by 546
Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., Chen, P., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30987-7 · Cited by 541
See, I., Su, J. R., Lale, A., Woo, E. J., Guh, A. Y., Shimabukuro, T. T., Streiff, M. B., Rao, A. K., Wheeler, A. P., Beavers, S. F., et al. (2021) · JAMA · doi:10.1001/jama.2021.7517 · Cited by 532
Tian, J.-H., Patel, N., Haupt, R., Zhou, H., Weston, S., Hammond, H., Logue, J., Portnoff, A. D., Norton, J., Guebre-Xabier, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20653-8 · Cited by 508
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
Wall, E. C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01290-3 · Cited by 491
Yang, S., Li, Y., Dai, L., Wang, J., He, P., Li, C., Fang, X., Wang, C., Zhao, X., Huang, E., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00127-4 · Cited by 442
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Liu, M. A. (2019) · Vaccines · doi:10.3390/vaccines7020037 · Cited by 427
Ella, R., Vadrevu, K. M., Jogdand, H., Prasad, S., Reddy, S., Sarangi, V., Ganneru, B., Sapkal, G., Yadav, P., Abraham, P., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30942-7 · Cited by 424
Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant
Liu, Y., Liu, J., Johnson, B. A., Xia, H., Ku, Z., Schindewolf, C., Widen, S. G., An, Z., Weaver, S. C., Menachery, V. D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110829 · Cited by 413
Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01446-y · Cited by 386
Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.002 · Cited by 378
Ella, R., Reddy, S., Jogdand, H., Sarangi, V., Ganneru, B., Prasad, S., Das, D., Raju, D., Praturi, U., Sapkal, G., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00070-0 · Cited by 378
Khan, A., Zia, T., Suleman, M., Khan, T., Ali, S. S., Abbasi, A. A., Mohammad, A., & Wei, D. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30367 · Cited by 345
Ella, R., Reddy, S., Blackwelder, W., Potdar, V., Yadav, P., Sarangi, V., Aileni, V. K., Kanungo, S., Rai, S., Reddy, P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02000-6 · Cited by 344
Milligan, I. D., Gibani, M. M., Sewell, R., Clutterbuck, E. A., Campbell, D., Plested, E., Nuthall, E., Voysey, M., Silva-Reyes, L., McElrath, M. J., et al. (2016) · JAMA · doi:10.1001/jama.2016.4218 · Cited by 324
Chang, J., Ciais, P., Gasser, T., Smith, P., Herrero, M., Havlík, P., Obersteiner, M., Guenet, B., Goll, D. S., Li, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20406-7 · Cited by 313
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Tostanoski, L. H., Wegmann, F., Martinot, A. J., Loos, C., McMahan, K., Mercado, N. B., Yu, J., Chan, C. N., Bondoc, S., Starke, C. E., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1070-6 · Cited by 286
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276
CDC COVID-19 Response Team, & Administration, F. A. D. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7004e1 · Cited by 269
ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · doi:10.1101/2020.05.13.093195 · Cited by 246
Li, X.-N., Huang, Y., Wang, W., Jing, Q.-L., Zhang, C.-H., Qin, P.-Z., Guan, W.-J., Gan, L., Li, Y.-L., Liu, W.-H., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1969291 · Cited by 235
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
Guebre-Xabier, M., Patel, N., Tian, J.-H., Zhou, B., Maciejewski, S., Lam, K., Portnoff, A. D., Massare, M. J., Frieman, M. B., Piedra, P. A., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.10.064 · Cited by 231
Electron microscopy of SARS-CoV-2: a challenging task
Goldsmith, C. S., Miller, S. E., Martines, R. B., Bullock, H. A., & Zaki, S. R. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31188-0 · Cited by 217
Tchesnokova, V., Kulasekara, H., Larson, L., Bowers, V., Rechkina, E., Kisiela, D., Sledneva, Y., Choudhury, D., Maslova, I., Deng, K., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00921-21 · Cited by 217
Schillie, S., Harris, A., Link-Gelles, R., Romero, J., Ward, J., & Nelson, N. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6715a5 · Cited by 208
Kremsner, P., Mann, P., Bosch, J., Fendel, R., Gabor, J. J., Kreidenweiss, A., Kroidl, A., Leroux-Roels, I., Leroux-Roels, G., Schindler, C., et al. (2020) · doi:10.1101/2020.11.09.20228551 · Cited by 199
Palacios, R., Batista, A. P., Albuquerque, C. S. N., Patiño, E. G., Santos, J. D. P., Tilli Reis Pessoa Conde, M., Piorelli, R. D. O., Pereira Júnior, L. C., Raboni, S. M., Ramos, F., et al. (2021) · doi:10.2139/ssrn.3822780 · Cited by 198
One year update on the COVID-19 pandemic: Where are we now?
Mishra, S. K., & Tripathi, T. (2021) · Acta Tropica · doi:10.1016/j.actatropica.2020.105778 · Cited by 191
Momin, T., Kansagra, K., Patel, H., Sharma, S., Sharma, B., Patel, J., Mittal, R., Sanmukhani, J., Maithal, K., Dey, A., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101020 · Cited by 185
Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., Zhang, B., Licata, C., Clark, T. A., & Shimabukuro, T. T. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7018e2 · Cited by 181
Prothrombotic immune thrombocytopenia after COVID-19 vaccination
Tiede, A., Sachs, U. J., Czwalinna, A., Werwitzke, S., Bikker, R., Krauss, J. K., Donnerstag, F., Weißenborn, K., Höglinger, G., Maasoumy, B., et al. (2021) · Blood · doi:10.1182/blood.2021011958 · Cited by 174
Kremsner, P. G., Ahuad Guerrero, R. A., Arana-Arri, E., Aroca Martinez, G. J., Bonten, M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00677-0 · Cited by 172
Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
Wang, G.-L., Wang, Z.-Y., Duan, L.-J., Meng, Q.-C., Jiang, M.-D., Cao, J., Yao, L., Zhu, K.-L., Cao, W.-C., & Ma, M.-J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2103022 · Cited by 167
Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., & Petsch, B. (2021) · npj Vaccines · doi:10.1038/s41541-021-00311-w · Cited by 165
Current advances in the development of SARS-CoV-2 vaccines
Awadasseid, A., Wu, Y., Tanaka, Y., & Zhang, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.52569 · Cited by 164
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
Watanabe, Y., Mendonça, L., Allen, E. R., Howe, A., Lee, M., Allen, J. D., Chawla, H., Pulido, D., Donnellan, F. R., Davies, H. D., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00080 · Cited by 157
Nhamo, G., Chikodzi, D., Kunene, H. P., & Mashula, N. (2020) · Global Public Health · doi:10.1080/17441692.2020.1860249 · Cited by 150
Covid-19: What new variants are emerging and how are they being investigated?
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n158 · Cited by 150
Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models
Dey, A., Rajanathan, T. M. C., Chandra, H., Pericherla, H. P. R., Mendiratta, S. K., Choonia, H. S., Bajpai, M., Singh, A. K., Sinha, A., Saini, G., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.098 · Cited by 147
D614G mutation of SARS-CoV-2 spike protein enhances viral infectivityPreprint
Hu, J., He, C., Gao, Q., Zhang, G., Cao, X., Long, Q., Deng, H., Huang, L., Chen, J., Wang, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.20.161323 · Cited by 143
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., Menachery, V. D., Weaver, S., Dormitzer, P. R., et al. (2021) · doi:10.1101/2021.01.07.425740 · Cited by 143
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Chiu, H.-P., Stevens, C. S., Vilardo, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24909-9 · Cited by 143
Sokołowska, M., Eiwegger, T., Ollert, M. W., Torres, M. J., Barber, D., Giacco, S. D., Jutel, M., Nadeau, K. C., Palomares, Ó., Rabin, R. L., et al. (2021) · Allergy · doi:10.1111/all.14739 · Cited by 138
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · doi:10.1101/2020.09.08.280818 · Cited by 126
Sapkal, G. N., Yadav, P. D., Ella, R., Deshpande, G. R., Sahay, R. R., Gupta, N., Vadrevu, K. M., Abraham, P., Panda, S., & Bhargava, B. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab051 · Cited by 121
de Souza, W. M., Amorim, M. R., Sesti‐Costa, R., Coimbra, L. D., Brunetti, N. S., de Toledo-Teixeira, D. A., de Souza, G. F., Muraro, S. P., Parise, P. L., Barbosa, P. P., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00129-4 · Cited by 119
Saito, A., Irie, T., Suzuki, R., Maemura, T., Nasser, H., Uriu, K., Kosugi, Y., Shirakawa, K., Sadamasu, K., Kimura, I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.17.448820 · Cited by 112
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
Choi, A., Koch, M., Wu, K., Dixon, G., Oestreicher, J., Legault, H. M., Stewart-Jones, G. B. E., Colpitts, T., Pajón, R., Bennett, H., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01313-21 · Cited by 112
Yadav, P. D., Ella, R., Kumar, S., Patil, D., Mohandas, S., Shete, A. M., Vadrevu, K. M., Bhati, G., Sapkal, G. N., Kaushal, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21639-w · Cited by 106
Ryzhikov, A. B., Bogryantseva, M. P., Usova, S. V., Даниленко, Е. Д., Августовна, Н. Е., Pyankov, O. V., Pyankova, O. G., Gudymo, A. S., Боднев, С. А., Сергеевна, О. Г., et al. (2021) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-asb-1699 · Cited by 106
Fratev, F. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01242 · Cited by 95
COVID-19 Vaccine and Myocarditis
Salah, H. M., & Mehta, J. L. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.07.009 · Cited by 93
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
Chen, Y., Shen, H., Huang, R., Tong, X., & Wu, C. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00287-5 · Cited by 92
Influenza vaccine: Where are we and where do we go?
Keshavarz, M., Mirzaei, H., Salemi, M., Momeni, F., Mousavi, M. J., Sadeghalvad, M., Arjeini, Y., Solaymani‐Mohammadi, F., Nahand, J. S., Namdari, H., et al. (2018) · Reviews in Medical Virology · doi:10.1002/rmv.2014 · Cited by 91
COVID-19 vaccine-induced myocarditis: Case report with literature review
Nassar, M., Nso, N., Gonzalez, C., Lakhdar, S., Alshamam, M. S., Elshafey, M., Abdalazeem, Y., Nyein, A., Punzalan, B., Durrance, R. J., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102205 · Cited by 90
RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?
Sandbrink, J. B., & Shattock, R. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608460 · Cited by 83
Hitchings, M. D. T., Ranzani, O., Dorión, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., Schulz, W. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26459-6 · Cited by 79
Ebola vaccine trials: progress in vaccine safety and immunogenicity
Matz, K. M., Marzi, A., & Feldmann, H. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1698952 · Cited by 78
Mohandas, S., Yadav, P. D., Shete-Aich, A., Abraham, P., Vadrevu, K. M., Sapkal, G., Mote, C., Nyayanit, D., Gupta, N., Srinivas, V. K., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102054 · Cited by 74
Fratev, F. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.23.424283 · Cited by 68
Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
Zhao, X., Zheng, A., Li, D., Zhang, R., Sun, H., Wang, Q., Gao, G. F., Han, P., & Dai, L. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00217-2 · Cited by 65
COVID vaccine excitement builds as Moderna reports third positive result
Callaway, E. (2020) · Nature · doi:10.1038/d41586-020-03248-7 · Cited by 58
Balakrishnan, V. S. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30709-x · Cited by 56
Ella, R., Reddy, S., Blackwelder, W., Potdar, V., Yadav, P. D., Sarangi, V., Aileni, V. K., Kanungo, S., Rai, S., Reddy, P., et al. (2021) · medRxiv · doi:10.1101/2021.06.30.21259439 · Cited by 50
mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
Rauch, S., Gooch, K., Hall, Y., Salguero, F. J., Dennis, M. J., Gleeson, F. V., Harris, D., Ho, C., Humphries, H. E., Longet, S., et al. (2020) · doi:10.1101/2020.12.23.424138 · Cited by 48
Maison, D. P., Ching, L. L., Shikuma, C. M., & Nerurkar, V. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.06.425497 · Cited by 47
de Souza, W. M., Amorim, M. R., Sesti‐Costa, R., Coimbra, L. D., de Toledo-Teixeira, D. A., Parise, P. L., Barbosa, P. P., Bispo-dos-Santos, K., Mofatto, L. S., Simeoni, C. L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3793486 · Cited by 45
Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concernPreprint
Jongeneelen, M. A. C., Kaszás, K., Veldman, D., Huizingh, J., van der Vlugt, R., Schouten, T. G., Zuijdgeest, D., Uil, T. G., Roey, G. V., Guimerà, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.01.450707 · Cited by 45
Immune responses to Sinopharm/ BBIBP‐CorV in individuals in Sri Lanka
Jeewandara, C., Aberathna, I. S., Pushpakumara, P. D., Kamaladasa, A., Guruge, D., Wijesinghe, A., Gunasekera, B., Tanussiya, S., Kuruppu, H., Ranasinghe, T., et al. (2022) · Immunology · doi:10.1111/imm.13536 · Cited by 42
COVID-19: A Brief Overview of the Discovery Clinical Trial
Eynde, J. J. V. (2020) · Pharmaceuticals · doi:10.3390/ph13040065 · Cited by 41
Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435972 · Cited by 41
A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations
Verghese, M., Jiang, B., Iwai, N., Mar, M., Sahoo, M. K., Yamamoto, F. F., Mfuh, K. O., Miller, J. A., Wang, H., Zehnder, J. L., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00741-21 · Cited by 40
Yadav, P. D., Sapkal, G. N., Ella, R., Sahay, R. R., Nyayanit, D. A., Patil, D. Y., Deshpande, G. R., Shete, A. M., Gupta, N., Mohan, V., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.05.447177 · Cited by 39
Tu, H., Avenarius, M. R., Kubatko, L. S., Hunt, M., Pan, X., Ru, P., Garee, J. P., Thomas, K., Mohler, P. J., Pancholi, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.12.426407 · Cited by 36
Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2
Ryzhikov, A. B., Ryzhikov, E. А., Bogryantseva, M. P., Даниленко, Е. Д., Иматдинов, И. Р., Августовна, Н. Е., Pyankov, O. V., Pyankova, O. G., Susloparov, I. M., Taranov, O. S., et al. (2021) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn1528 · Cited by 36
Parry, H., Tut, G., Bruton, R. K., Faustini, S. E., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K. E., Amirthalingam, G., et al. (2021) · eLife · doi:10.7554/elife.69375 · Cited by 36
Wang, Z.-J., Zhang, H., Lu, J., Xu, K.-W., Peng, C., Guo, J. H., Gao, X.-X., Wan, X. H., Wang, W.-H., Shan, C., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1852059 · Cited by 32
Origin, evolution and global spread of SARS-CoV-2
Zhukova, A., Blassel, L., Lemoine, F., Morel, M. H., Voznica, J., & Gascuel, O. (2020) · Comptes Rendus Biologies · doi:10.5802/crbiol.29 · Cited by 30
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-400230/v1 · Cited by 27
A tale of three SARS-CoV-2 variants with independently acquired P681H mutations in New York StatePreprint
Lasek‐Nesselquist, E., Pata, J. D., Schneider, E., & George, K. S. (2021) · medRxiv · doi:10.1101/2021.03.10.21253285 · Cited by 23
Hassine, I. H., Gharbi, J., Hamrita, B., Almalki, M. A., Rodrígúez, J. F., & M’hadheb-Gharbi, M. B. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05333-6 · Cited by 20
Yadav, P. D., Kumar, S., Agarwal, K., Jain, M., Patil, D., Maithal, K., Mathapati, B., Giri, S. R., Mohandas, S., Shete, A. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.02.429480 · Cited by 20
Kremsner, P. G., Guerrero, R. A. A., Arana, E., Aroca Martinez, G. J., Bonten, M. J. M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2021) · doi:10.2139/ssrn.3911826 · Cited by 17
Parry, H., Tut, G., Faustini, S. E., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K. E., Amirthalingam, G., Charlton, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3816840 · Cited by 17
Parry, H., Tut, G., Zuo, J., & Moss, P. A. H. (2021) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.4740080 · Cited by 12
Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., et al. (2021) · doi:10.1101/2021.08.13.456316 · Cited by 8
Metadata
- Authors
- Hadj Hassine, I.
- Venue
- Reviews in Medical Virology
- Publisher
- Wiley
- Published
- 2021-11-09
- Volume
- 32
- Issue
- 4
- Pages
- e2313-e2313
- ISSN
- 1052-9276 (ISSN-L)
- 1099-1654
- OpenAlex
- W3213666150
- Cited by
- 383
- References
- 134
- FWCI
- 21.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.